Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 2/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.44 |
| ▸ | FABP6 | P51161 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | TYMS | P04818 | 1/20 | 0.31 |
| ▸ | RAF1 | P04049 | 1/20 | 0.30 |
| ▸ | BRAF | P15056 | 1/20 | 0.30 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2491924 | 0.89 | AURKA (0.45) | AURKAAURKBFABP6CHEK1SRC | |
| SCHEMBL13367949 | 0.84 | AURKA (0.47) | AURKAAURKBFABP6CHEK1SRC | |
| SCHEMBL2491051 | 0.81 | AURKA (0.41) | AURKAAURKBFABP6CHEK1SRC | |
| SCHEMBL2487407 | 0.81 | AURKA (0.64) | AURKAAURKBFABP6CHEK1SRC | |
| SCHEMBL2489292 | 0.79 | AURKA (0.53) | AURKAAURKBFABP6CHEK1SRC | |
| SCHEMBL2491389 | 0.78 | AURKA (0.33) | AURKAAURKB | |
| SCHEMBL13341619 | 0.77 | NPC1 (0.44) | RAF1BRAF | |
| SCHEMBL3425001 | 0.77 | AURKA (0.41) | AURKAAURKBFABP6CHEK1SRC | |
| SCHEMBL2492581 | 0.77 | AURKA (0.41) | AURKAAURKBFABP6CHEK1SRC | |
| SCHEMBL2513543 | 0.76 | AURKA (0.50) | AURKAAURKBFABP6CHEK1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7714010-B2 | Pyrrolobenzimidazolones and their use as anti-proliferative agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-11 | — | — | US | disclosed |
| US-7714010-B2 | Pyrrolobenzimidazolones and their use as anti-proliferative agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-11 | — | — | US | disclosed |
| US-20050261350-A1 | Pyrrolobenzimidazolones and their use as anti-proliferative agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261350-A1 | Pyrrolobenzimidazolones and their use as anti-proliferative agents | MKI67, CCNI, CCNA1 | AURKA 268/4885AURKB 215/4885FABP6 2523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.